Sanofi, Merck get Vaxelis approval
Sanofi and Merck have received the Food and Drug Administration’s blessing for Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age, or prior to the 5th birthday.
Vaxelis was developed as part of a joint partnership between Sanofi and Merck.
Commercial supply will not be available in the United States prior to 2020.
Vaxelils is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).
Vaxelis was developed as part of a joint partnership between Sanofi and Merck.
Commercial supply will not be available in the United States prior to 2020.
Vaxelils is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).